Journal of Clinical and Experimental Hematopathology
Online ISSN : 1880-9952
Print ISSN : 1346-4280
ISSN-L : 1346-4280
Case Study
Sustained Remission after Rituximab-containing
Chemotherapy for Intravascular Large B-cell Lymphoma
Kazuyuki ShimadaHiroshi KosugiHiroto NarimatsuSatoko ShimadaTatsuya SuzukiMasafumi ItoTomohiro KinoshitaNaoyoshi MoriTomoki Naoe
Author information

2008 Volume 48 Issue 1 Pages 25-28


Intravascular large B-cell lymphoma (IVL) is rare aggressive disseminated lymphoma associated with poor outcomes. Rituximab is a novel molecular agent that can reportedly improve outcomes for patients with diffuse large B-cell lymphoma. However, the safety and efficacy of rituximab in patients with IVL are unclear. A 76-year-old woman was hospitalized due to altered consciousness, fever and respiratory abnormalities. Definitive diagnosis of IVL was obtained following repeated biopsies of bone marrow. The patient received chemotherapy consisting of cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP), and achieved complete remission after 3 courses of treatment. She has remained in complete remission for over 3 years after diagnosis. This report suggests that rituximab-containing regimens could be safe and effective for elderly patients with IVL. [J Clin Exp Hematopathol 48(1) : 25-28, 2008]

Content from these authors
© 2008 by The Japanese Society for Lymphoreticular Tissue Research
Previous article Next article